Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.56 |
| ▸ | CASP3 | P42574 | 7/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | CASP9 | P55211 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31346580 | 1.00 | REN (0.56) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL28712274 | 1.00 | REN (0.56) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL15012737 | 1.00 | REN (0.56) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL24310886 | 1.00 | REN (0.56) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL23133185 | 0.97 | REN (0.57) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL21481182 | 0.97 | REN (0.57) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL21481185 | 0.97 | REN (0.57) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL23133184 | 0.97 | REN (0.57) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL20257211 | 0.95 | REN (0.55) | RENCASP3CASP1CASP7CASP9 | |
| SCHEMBL17494194 | 0.92 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | GENERATION BIO CO. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | STING1, DCLRE1B, DCLRE1A | REN 4257/4885CASP3 929/4885CASP1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.